Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash & Current Investments (2016 - 2025)

Marimed (MRMD) has disclosed Cash & Current Investments for 15 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments fell 32.61% to $6.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.6 million, a 32.61% decrease, with the full-year FY2024 number at $7.3 million, down 50.57% from a year prior.
  • Cash & Current Investments was $6.6 million for Q3 2025 at Marimed, up from $6.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $34.7 million in Q1 2022 to a low of $6.1 million in Q2 2025.
  • A 5-year average of $14.7 million and a median of $13.4 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 683.72% in 2021, then plummeted 67.06% in 2022.
  • Marimed's Cash & Current Investments stood at $29.9 million in 2021, then plummeted by 67.06% to $9.9 million in 2022, then skyrocketed by 49.42% to $14.7 million in 2023, then plummeted by 50.57% to $7.3 million in 2024, then dropped by 9.42% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Cash & Current Investments are $6.6 million (Q3 2025), $6.1 million (Q2 2025), and $7.2 million (Q1 2025).